Building resilience needs to be central to treating drug-resistant tuberculosis

  19 March 2021

The arrival of new medications, such as bedaquiline and delamanid, to treat the half million individuals who develop drug-resistant tuberculosis (DRTB) globally each year has raised hope that both treatment access and individual patient outcomes can be improved. However, together with increasing discourse around providing more patient-centred care in tuberculosis, there is a growing body of literature describing the experiences of individuals going through DRTB treatment. In The Lancet Global Health, Amrita Daftary and colleagues add to this literature by describing distinct stages through DRTB diagnosis and treatment from the point of view of patients with DRTB and HIV in KwaZulu-Natal province, South Africa. The study emphasises that despite improvements in treatment, including shorter, all-oral regimens that include bedaquiline, DRTB treatment remains lengthy, difficult, and life-changing for individuals.

Further reading: The Lancet Gobal Health
Author(s): Helen Cox, Marian Loveday
Healthy Patients  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!